07/30/2026
Viruses evolve quickly, often finding ways to escape antiviral drugs. A new study led by WID undergraduate Shiv Muthupandiyan explores whether new antiviral therapies could evolve alongside them. The research focuses on defective interfering particles, or DIPs, mutant viral particles that act as parasites of viruses. DIPs cannot reproduce on their own, so they use a virus’s replication machinery and consume resources inside infected cells, slowing viral growth. By modeling how viruses and DIPs adapt to one another over time, the study offers a new way to think about antiviral therapies that may be better able to resist viral escape.
Shriv Muthupandiyan Viruses have parasites of their own, and those tiny hitchhikers may help determine how viruses change, survive and respond to treatment. Undergraduate researcher Shiv Muthupandiyan of the John Yin Lab at